Many studies have shown that TOP2A can be a prognostic biomarker and potential therapeutic target for bladder cancer, such as bladder urothelial carcinoma (BLCA), lung adenocarcinoma, prostate cancer, colon cancer and breast cancer [12–16]. The gene discussed is TOP2A; the disease is breast cancer.